| Accession |
PRJCA042908 |
| Title |
Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase II trial |
| Relevance |
Medical |
| Data types |
Targeted Locus (Loci)
Transcriptome or Gene expression
|
| Organisms |
Homo sapiens
|
| Description |
This study aimed to evaluate the combination of sintilimab and anlotinib in treatment-naive mCRC patients. This was an investigator-initiated, open-label, single-arm, phase II trial conducted in treatment-naive mCRC patients. Eligible patients received sintilimab 200 mg intravenously on day 1, plus anlotinib 12 mg orally daily from days 1 to 14, with a treatment cycle of every 3 weeks. The primary endpoint was the objective response rate (ORR), assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. |
| Sample scope |
Multiisolate |
| Release date |
2025-07-09 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 40954146
|
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial
|
Signal Transduction and Targeted Therapy
|
10.1038/s41392-025-02383-9
|
2025
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Shanghai Changzheng Hospital
|
|
2019SL036
|
|
|
|
| Submitter |
Dongyu
Liu (dongyu.liu@3dmedcare.com)
|
| Organization |
3D Medicines Inc. |
| Submission date |
2025-07-09 |
